|
Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine Clinical research trials and Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine. Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine clinical trial. Subjects often receive the most expert healthcare possible for their Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine  Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine
Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine
For Condition: Guillain-Barre Syndrome
Status: Recruiting
Sponsor(s): FDA Office of Orphan Products Development ,
Synopsis: In developed countries, Guillain-Barre Syndrome (GBS) is the most common cause of acute neuromuscular paralysis, afflicting about 5,000 persons annually in the United States. Over 20% of GBS patients have permanent residual motor deficits that affect their activities of daily living. The goal of this study is to assess the potential usefulness and safety of 4-aminopyridine (4-AP) in those patients who suffer chronic functional deficits from GBS.This medication is a potassium channel blocker that has the potential to improve nerve conduction, particularly across partially demyelinated axons. It is felt that by increasing nerve conduction there will be improved motor performance for walking and activities of daily living, as well as decreased fatiguability. This medication has demonstrated potential usefulness in central demyelinating diseases such as multiple sclerosis.Because the peripheral nervous system is much more accessible to systemic medication delivery it is felt that this medication may improve the functional status of those patients who are suffering from the residual side effects of this medication.
Details: Objective.- To determine the safety and efficacy of orally delivered 4-aminopyridine for motor weakness due to Guillain-Barre Syndrome (GBS) under a FDA approved protocol (IND No: 58,029). Setting.- Tertiary care outpatient rehabilitation center directly attached to a university hospital. Subjects.- Subjects who are unable to ambulate more than 200 feet without assistive devices and have residual nonprogressive motor weakness due to GBS more than one year out from the initial episode. Design.- Subjects will be randomized to a double-blind, placebo-controlled, cross-over design, which had two eight-week treatment arms with a three-week washout. The average dosage at 4 weeks will be 30 milligrams (mg) per day. Patients who demonstrate improvement will be continued on the medication for an additional three months. Assessments will be performed every two weeks during the randomized trial and every month for those continued for up to three months on the medication.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 19 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Male or Female, 19 to 75 years of age, irrespective of race. - Subject is able to and has voluntarily given informed consent prior to the performance of any study specific procedures. - Subject has neurological impairment secondary to GBS, which has been stable for more than 12 months. - Subject has motor strength that averages less than 5.0 but greater than 3.0 on the ASIA motor scale. - Subject is able and willing to comply with protocol. - Subjects will agree to no change in their outpatient therapy, or home exercise programs during enrollment in the study.
Total Enrollment: 30
Location and Contact Information:
Spain Rehabilitation Center, UAB Hospital *Recruiting*
Birmingham, Alabama, 35249-7330
United States
Recruiting Jay Meythaler 205-934-2088
Additional Information:
Study ID Numbers: 2129;
Study Start Date: September 2002
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056810
Other Guillain-Barre Syndrome Studies:
1. Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome
2. Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine
Related Studies:
Other Guillain-Barre Syndrome Clinical Trials
Other Alabama Clinical Trials
Other Birmingham Clinical Trials
Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine
|
|
|
|
|
|
|
|
